[{"id":"cd9c94c5-ad9b-4ee8-a453-d749f2f2d4c8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05111574","created_at":"2021-11-08T14:53:11.866Z","updated_at":"2025-02-25T12:38:02.656Z","phase":"Phase 2","brief_title":"Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery","source_id_and_acronym":"NCT05111574","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 99","initiation":"Initiation: 08/11/2022","start_date":" 08/11/2022","primary_txt":" Primary completion: 12/19/2025","primary_completion_date":" 12/19/2025","study_txt":" Completion: 12/19/2025","study_completion_date":" 12/19/2025","last_update_posted":"2025-02-24"},{"id":"0a44475b-ada6-49fd-a78d-da7cabf4adaa","acronym":"","url":"https://clinicaltrials.gov/study/NCT02879162","created_at":"2021-01-18T14:08:03.022Z","updated_at":"2025-02-25T14:14:51.028Z","phase":"Phase 2","brief_title":"Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours","source_id_and_acronym":"NCT02879162","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)"],"overall_status":"Completed","enrollment":" Enrollment 140","initiation":"Initiation: 12/14/2016","start_date":" 12/14/2016","primary_txt":" Primary completion: 06/20/2021","primary_completion_date":" 06/20/2021","study_txt":" Completion: 01/29/2025","study_completion_date":" 01/29/2025","last_update_posted":"2025-02-17"},{"id":"c30bda4b-7e9e-488f-9635-25027af3f695","acronym":"","url":"https://clinicaltrials.gov/study/NCT05303493","created_at":"2022-03-31T18:53:02.337Z","updated_at":"2025-02-25T14:41:16.078Z","phase":"Phase 1","brief_title":"Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and Melanoma","source_id_and_acronym":"NCT05303493","lead_sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","biomarkers":" PD-L1 • BRAF","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 06/29/2022","start_date":" 06/29/2022","primary_txt":" Primary completion: 04/15/2025","primary_completion_date":" 04/15/2025","study_txt":" Completion: 04/15/2027","study_completion_date":" 04/15/2027","last_update_posted":"2025-02-14"},{"id":"8faa9c2f-7698-40c3-8644-3401597d3da2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05628883","created_at":"2022-11-29T15:57:45.457Z","updated_at":"2025-02-25T16:33:12.261Z","phase":"Phase 1","brief_title":"Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma","source_id_and_acronym":"NCT05628883","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" BRAF • IL2","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TIDAL-01"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 11/22/2022","start_date":" 11/22/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-07"},{"id":"bdabf0d8-2cf8-415a-871a-05a580f1c107","acronym":"SWOG S1801","url":"https://clinicaltrials.gov/study/NCT03698019","created_at":"2021-01-29T07:18:05.054Z","updated_at":"2025-02-25T16:37:13.668Z","phase":"Phase 2","brief_title":"A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma","source_id_and_acronym":"NCT03698019 - SWOG S1801","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 313","initiation":"Initiation: 02/15/2019","start_date":" 02/15/2019","primary_txt":" Primary completion: 09/01/2022","primary_completion_date":" 09/01/2022","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2025-02-06"},{"id":"45804b31-abb5-4caf-bfa4-174bafa136c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT02535078","created_at":"2021-01-18T12:15:32.419Z","updated_at":"2025-02-25T15:06:47.576Z","phase":"Phase 1/2","brief_title":"Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma","source_id_and_acronym":"NCT02535078","lead_sponsor":"Immunocore Ltd","biomarkers":" BRAF • HLA-A","pipe":" | ","alterations":" BRAF mutation • HLA-A*02:01 • HLA-A*02","tags":["BRAF • HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • HLA-A*02:01 • HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Kimmtrak (tebentafusp-tebn)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/01/2015","start_date":" 11/01/2015","primary_txt":" Primary completion: 06/19/2023","primary_completion_date":" 06/19/2023","study_txt":" Completion: 09/06/2023","study_completion_date":" 09/06/2023","last_update_posted":"2024-07-24"},{"id":"9795b4cb-6f73-4ce5-a9a8-6ba8acc8d386","acronym":"Keynote MK-3475-B66","url":"https://clinicaltrials.gov/study/NCT03611868","created_at":"2021-01-18T17:45:12.835Z","updated_at":"2025-02-25T16:08:10.551Z","phase":"Phase 1/2","brief_title":"A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors","source_id_and_acronym":"NCT03611868 - Keynote MK-3475-B66","lead_sponsor":"Ascentage Pharma Group Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" ATM mutation • TP53 wild-type","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • alrizomadlin (APG-115)"],"overall_status":"Recruiting","enrollment":" Enrollment 230","initiation":"Initiation: 08/29/2018","start_date":" 08/29/2018","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 03/30/2025","study_completion_date":" 03/30/2025","last_update_posted":"2024-07-19"},{"id":"f2ce9fa4-3f0b-4aee-a86d-f80098e3eb24","acronym":"Neo PeLeMM","url":"https://clinicaltrials.gov/study/NCT05545969","created_at":"2022-09-19T13:55:47.813Z","updated_at":"2025-02-25T16:18:09.663Z","phase":"Phase 2","brief_title":"Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma","source_id_and_acronym":"NCT05545969 - Neo PeLeMM","lead_sponsor":"Melanoma Institute Australia","biomarkers":" HIF1A","pipe":" | ","alterations":" HIF1A expression","tags":["HIF1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HIF1A expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/01/2024","start_date":" 03/01/2024","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2036","study_completion_date":" 05/01/2036","last_update_posted":"2024-06-26"},{"id":"0026ad65-8d38-4ca2-8a0a-0d46b06b1f05","acronym":"SWOG S1616","url":"https://clinicaltrials.gov/study/NCT03033576","created_at":"2021-01-18T14:55:53.378Z","updated_at":"2024-07-02T16:34:25.875Z","phase":"Phase 2","brief_title":"Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma","source_id_and_acronym":"NCT03033576 - SWOG S1616","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" CD8 expression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 94","initiation":"Initiation: 10/23/2017","start_date":" 10/23/2017","primary_txt":" Primary completion: 09/19/2023","primary_completion_date":" 09/19/2023","study_txt":" Completion: 12/12/2024","study_completion_date":" 12/12/2024","last_update_posted":"2024-06-14"},{"id":"28ed5efa-c5b5-4262-aa3e-54b883b60ead","acronym":"ARTISTRY-3","url":"https://clinicaltrials.gov/study/NCT04592653","created_at":"2021-01-19T20:28:47.499Z","updated_at":"2024-07-02T16:34:37.223Z","phase":"Phase 1/2","brief_title":"Less Frequent IV Dosing \u0026 Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)","source_id_and_acronym":"NCT04592653 - ARTISTRY-3","lead_sponsor":"Mural Oncology, Inc","biomarkers":" MSI • NCAM1","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI • NCAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • nemvaleukin alfa (ALKS 4230)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 09/30/2020","start_date":" 09/30/2020","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-06-07"},{"id":"c335841a-9799-446b-a29a-af88ce1a32f9","acronym":"Keynote-151","url":"https://clinicaltrials.gov/study/NCT02821000","created_at":"2021-01-18T13:50:00.779Z","updated_at":"2024-07-02T16:35:00.014Z","phase":"Phase 1","brief_title":"Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151/KEYNOTE-151)","source_id_and_acronym":"NCT02821000 - Keynote-151","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" BRAF","pipe":" | ","alterations":" PD-L1 expression • BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Completed","enrollment":" Enrollment 103","initiation":"Initiation: 07/08/2016","start_date":" 07/08/2016","primary_txt":" Primary completion: 12/27/2017","primary_completion_date":" 12/27/2017","study_txt":" Completion: 11/30/2022","study_completion_date":" 11/30/2022","last_update_posted":"2024-05-30"},{"id":"a4fa2c9b-d0d8-45aa-8666-8374568e8a92","acronym":"EBIN","url":"https://clinicaltrials.gov/study/NCT03235245","created_at":"2021-01-18T15:59:13.644Z","updated_at":"2024-07-02T16:35:00.361Z","phase":"Phase 2","brief_title":"Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib","source_id_and_acronym":"NCT03235245 - EBIN","lead_sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 271","initiation":"Initiation: 10/30/2018","start_date":" 10/30/2018","primary_txt":" Primary completion: 10/24/2023","primary_completion_date":" 10/24/2023","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-05-29"},{"id":"af5b2b8c-e254-4a25-b607-944acb5d90e8","acronym":"SWOG S1404","url":"https://clinicaltrials.gov/study/NCT02506153","created_at":"2021-01-18T12:05:51.420Z","updated_at":"2024-07-02T16:35:01.870Z","phase":"Phase 3","brief_title":"Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery","source_id_and_acronym":"NCT02506153 - SWOG S1404","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • Intron A (interferon α-2b) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1345","initiation":"Initiation: 11/10/2015","start_date":" 11/10/2015","primary_txt":" Primary completion: 09/15/2023","primary_completion_date":" 09/15/2023","study_txt":" Completion: 01/23/2025","study_completion_date":" 01/23/2025","last_update_posted":"2024-05-22"},{"id":"a4243371-e966-46ad-813b-48b6cc83f0e3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02858869","created_at":"2021-01-18T14:01:58.994Z","updated_at":"2025-02-25T16:05:04.203Z","phase":"Phase 1","brief_title":"Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases","source_id_and_acronym":"NCT02858869","lead_sponsor":"Emory University","biomarkers":" PD-L1 • BRAF • ALK","pipe":"","alterations":" ","tags":["PD-L1 • BRAF • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 10/04/2016","start_date":" 10/04/2016","primary_txt":" Primary completion: 11/19/2020","primary_completion_date":" 11/19/2020","study_txt":" Completion: 10/28/2023","study_completion_date":" 10/28/2023","last_update_posted":"2024-05-13"},{"id":"080b8b58-50bf-4327-9274-58c6a55f5dce","acronym":"","url":"https://clinicaltrials.gov/study/NCT04493203","created_at":"2021-01-18T21:35:04.129Z","updated_at":"2025-02-25T14:29:28.960Z","phase":"Phase 2","brief_title":"Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma","source_id_and_acronym":"NCT04493203","lead_sponsor":"Yana Najjar","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • axitinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 12/18/2020","start_date":" 12/18/2020","primary_txt":" Primary completion: 04/15/2024","primary_completion_date":" 04/15/2024","study_txt":" Completion: 02/28/2029","study_completion_date":" 02/28/2029","last_update_posted":"2024-05-07"},{"id":"711124ce-0659-42bd-8b65-60940e5975b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05415072","created_at":"2022-06-10T12:58:54.272Z","updated_at":"2024-07-02T16:35:07.121Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas","source_id_and_acronym":"NCT05415072","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" GNAQ","pipe":"","alterations":" ","tags":["GNAQ"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DYP688"],"overall_status":"Recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 07/04/2022","start_date":" 07/04/2022","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2024-04-29"},{"id":"2af63127-3115-4ddf-9da7-0032fefe8e92","acronym":"iPREDICT","url":"https://clinicaltrials.gov/study/NCT05013099","created_at":"2021-08-19T14:52:55.130Z","updated_at":"2024-07-02T16:35:10.176Z","phase":"Phase 2","brief_title":"Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies","source_id_and_acronym":"NCT05013099 - iPREDICT","lead_sponsor":"ImaginAb, Inc.","biomarkers":" PD-L1 • KRAS • CD8 • PD-1","pipe":" | ","alterations":" PD-L1 expression • KRAS mutation • KRAS G12C • MET mutation • CD8 expression","tags":["PD-L1 • KRAS • CD8 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • KRAS mutation • KRAS G12C • MET mutation • CD8 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 12/09/2021","start_date":" 12/09/2021","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-04-11"},{"id":"38d6c31c-a42e-4154-b3f7-edcf460d915e","acronym":"NCI-2018-01211","url":"https://clinicaltrials.gov/study/NCT03025256","created_at":"2021-01-18T14:53:25.115Z","updated_at":"2024-07-02T16:35:10.137Z","phase":"Phase 1","brief_title":"Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease","source_id_and_acronym":"NCT03025256 - NCI-2018-01211","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRAF • IL2","pipe":"","alterations":" ","tags":["BRAF • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 05/02/2018","start_date":" 05/02/2018","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2024-04-11"},{"id":"5cbbdbd0-828a-4f3e-b2da-6d260cfea60d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05913388","created_at":"2023-06-22T19:11:35.572Z","updated_at":"2024-07-02T16:35:10.707Z","phase":"Phase 2","brief_title":"GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT05913388","lead_sponsor":"Providence Health \u0026 Services","biomarkers":" LGALS3","pipe":"","alterations":" ","tags":["LGALS3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • selvigaltin (GB1211)"],"overall_status":"Recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 02/29/2024","start_date":" 02/29/2024","primary_txt":" Primary completion: 02/01/2028","primary_completion_date":" 02/01/2028","study_txt":" Completion: 02/01/2030","study_completion_date":" 02/01/2030","last_update_posted":"2024-04-09"},{"id":"2f59a817-0e8b-44c9-812f-3c051a1229d1","acronym":"LUMINOS-102","url":"https://clinicaltrials.gov/study/NCT04577807","created_at":"2021-01-18T21:51:05.215Z","updated_at":"2024-07-02T16:35:11.133Z","phase":"Phase 2","brief_title":"LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma","source_id_and_acronym":"NCT04577807 - LUMINOS-102","lead_sponsor":"Istari Oncology, Inc.","biomarkers":" PD-L1 • BRAF • CD8","pipe":" | ","alterations":" PD-L1 expression • BRAF mutation • BRAF wild-type","tags":["PD-L1 • BRAF • CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF mutation • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lerapolturev (PVS-RIPO)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 11/17/2020","start_date":" 11/17/2020","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2024-04-05"},{"id":"e6a761ac-dd0a-4052-9115-9278013bbd57","acronym":"","url":"https://clinicaltrials.gov/study/NCT02519322","created_at":"2021-01-18T12:10:30.425Z","updated_at":"2025-02-25T16:30:41.228Z","phase":"Phase 2","brief_title":"Neoadjuvant and Adjuvant Checkpoint Blockade","source_id_and_acronym":"NCT02519322","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016)"],"overall_status":"Completed","enrollment":" Enrollment 53","initiation":"Initiation: 02/02/2016","start_date":" 02/02/2016","primary_txt":" Primary completion: 01/26/2023","primary_completion_date":" 01/26/2023","study_txt":" Completion: 01/26/2023","study_completion_date":" 01/26/2023","last_update_posted":"2024-04-05"},{"id":"f44f76e4-0ba3-4481-b09e-d12b99a9cec1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05655312","created_at":"2022-12-19T15:59:21.058Z","updated_at":"2024-07-02T16:35:11.693Z","phase":"Phase 1/2","brief_title":"MC1R-targeted Alpha-particle Therapy Trial in Adults With Advanced Melanoma","source_id_and_acronym":"NCT05655312","lead_sponsor":"Perspective Therapeutics","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VMT-01"],"overall_status":"Recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 06/01/2023","start_date":" 06/01/2023","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2024-04-03"},{"id":"3acfa9f6-10ca-4b1d-bfea-249843456580","acronym":"ARTISTRY-6","url":"https://clinicaltrials.gov/study/NCT04830124","created_at":"2021-04-02T11:53:53.927Z","updated_at":"2024-07-02T16:35:13.615Z","phase":"Phase 2","brief_title":"Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6","source_id_and_acronym":"NCT04830124 - ARTISTRY-6","lead_sponsor":"Mural Oncology, Inc","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nemvaleukin alfa (ALKS 4230)"],"overall_status":"Recruiting","enrollment":" Enrollment 176","initiation":"Initiation: 05/27/2021","start_date":" 05/27/2021","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-03-20"},{"id":"39c6b350-3479-44ce-a2c9-487a64f9b6ef","acronym":"MEL60","url":"https://clinicaltrials.gov/study/NCT02126579","created_at":"2021-01-29T07:06:15.841Z","updated_at":"2024-07-02T16:35:17.147Z","phase":"Phase 1/2","brief_title":"Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists","source_id_and_acronym":"NCT02126579 - MEL60","lead_sponsor":"Craig L Slingluff, Jr","biomarkers":" CD8 • IFNG","pipe":"","alterations":" ","tags":["CD8 • IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 05/01/2014","start_date":" 05/01/2014","primary_txt":" Primary completion: 11/20/2019","primary_completion_date":" 11/20/2019","study_txt":" Completion: 05/05/2021","study_completion_date":" 05/05/2021","last_update_posted":"2024-02-28"}]